Castle Biosciences, Inc. (CSTL)
NASDAQ: CSTL · IEX Real-Time Price · USD
19.65
-0.27 (-1.36%)
Jul 22, 2024, 10:09 AM EDT - Market open
Castle Biosciences Employees
Castle Biosciences had 610 employees as of December 31, 2023. The number of employees increased by 67 or 12.34% compared to the previous year.
Employees
610
Change (1Y)
67
Growth (1Y)
12.34%
Revenue / Employee
$411,025
Profits / Employee
-$50,485
Market Cap
541.93M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Quanterix | 441 |
National Research | 435 |
Alector | 244 |
iTeos Therapeutics | 157 |
OmniAb | 106 |
Terns Pharmaceuticals | 66 |
Mind Medicine (MindMed) | 57 |
Mereo BioPharma Group | 33 |
CSTL News
- 7 days ago - Castle Biosciences to Release Second Quarter 2024 Financial Results and Host Conference Call on Monday, Aug. 5, 2024 - Business Wire
- 11 days ago - Castle Biosciences Honored with Top Workplaces Awards - Business Wire
- 14 days ago - Top 5 Health Care Stocks That May Explode In July - Benzinga
- 4 weeks ago - Recent AGA Clinical Practice Guideline Acknowledges That Individuals Who May Be at Increased Risk of Progression to Esophageal Cancer Might Be Identified Using Tissue-Based Biomarkers, Particularly Castle Biosciences' TissueCypher® Test - Business Wire
- 4 weeks ago - Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 5 weeks ago - Castle Biosciences' Founder, President and CEO Derek Maetzold Named an EY Entrepreneur Of The Year® 2024 Gulf South Award Winner - Business Wire
- 7 weeks ago - Castle Biosciences to Present New Data at 2024 ASCO® Annual Meeting Highlighting Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Metastasis to the Central Nervous System to Prompt Use of Imaging Surveillance - Business Wire
- 7 weeks ago - New Publication Shows DecisionDx®-SCC Identifies High-Risk Squamous Cell Carcinoma Patients Who Are Likely to Benefit from Adjuvant Radiation Therapy and Those Who Can Consider Deferring Treatment Based on Biological Risk of Metastasis - Business Wire